Related Experiment Video
Updated: Oct 6, 2025
07:30
Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
Published on: May 10, 2018
9.4K
Development of a Novel Insulin Sensor for Clinical Decision-Making
Eva Vargas1, Eleonora M Aiello2,3, Jordan E Pinsker3
1Department of Nanoengineering, University of California San Diego, La Jolla, CA, USA.
Journal of Diabetes Science and Technology
|January 19, 2022
Summary
A new disposable electrochemical sensor enables rapid, sensitive, and low-cost point-of-care insulin detection. This innovation aims to improve individualized diabetes management through frequent insulin measurements outside traditional lab settings.
Area of Science:
- Biomedical Engineering
- Analytical Chemistry
- Diabetes Technology
Background:
- Current diabetes management relies on centralized lab-based insulin measurements, hindering frequent monitoring.
- Individualized diabetes care requires real-time insulin data for better treatment algorithms.
- A decentralized, point-of-care (POC) insulin testing solution is needed.
Purpose of the Study:
- To develop and optimize a novel decentralized disposable electrochemical insulin sensor.
- To achieve high analytical and operational performance for clinical on-site insulin testing.
- To enable true POC insulin detection for enhanced diabetes management.
Main Methods:
- Development and optimization of a novel disposable electrochemical insulin sensor.
- Focus on achieving high sensitivity, rapid detection, and operational stability.
- Fabrication designed for scalability and low-cost production.
Main Results:
- The insulin immunosensor detects endogenous and analog insulin with high sensitivity (30.2 pM LOD).
- Features rapid time-to-result, stability for remote use, and low-cost fabrication (<$5 per disposable).
- Detects insulin in ≤10 µL undiluted serum within 30 minutes.
Conclusions:
- The developed insulin sensor is suitable for frequent insulin monitoring in remote clinical settings.
- Potential application in improving individualized diabetes management through POC testing.
- Future clinical studies will assess efficacy in type 1 diabetes patients.
Related Concept Videos
01:28Insulin: The Receptor and Signaling Pathways
1.7K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.7K
01:25Insulin: Biosynthesis, Chemistry, and Preparation
634
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
634
01:27Insulin Formulations: Types and Delivery
299
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
299
01:16Insulin: Dosing Regimen and Adverse Effects
295
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
295